AI Stock Memo: RLMD - Relmada Therapeutics - RankAlpha

RLMD

Rating neutralAI Memo

Relmada Therapeutics

As of 2026-04-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

NDV-01 U.S. IND clearance / Phase 3 start target in mid-2026 • 2026-06-30

Expected move: +9%

Biggest risk

The bear case is that the company is still rebuilding after terminating REL-1017, has no clinical readout in hand for the new strategy, and may need more capital beyond the stated 12-month funding window if development scope expands [#10-K-2026-03-19].

Invalidation

Break below $5 or thesis failure.

What would change my mind?

The bull case is that RLMD now has a reset pipeline with NDV-01 as the lead asset, sepranolone as a second program, and enough cash to reach targeted mid-2026 development milestones; successful IND/trial-start execution could move the stock closer to its sparse published target backdrop [#10-K-2026-03-19].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-17

Base target

p=45%

Bull target

$10

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway supports near-term milestones but likely not a full multi-program buildout without more capital
The bull case is that RLMD now has a reset pipeline with NDV-01 as the lead asset, sepranolone as a second program, and enough cash to reach targeted mid-2026 development milestones; successful IND/trial-start execution could move the stock closer to its sparse published target backdrop [#10-K-2026-03-19].
At a $7 anchor price and roughly $310 million market cap, RLMD screens as a small-cap biotech option on milestone delivery; with no broad analyst coverage count and only management-set mid-2026 milestones, valuation looks more like a monitoring setup than a high-conviction mispricing.

BearKey bullets

Additional financing or partnering may be needed beyond the stated 12-month funding horizon.
Mid-2026 IND and trial-start timelines may slip.
Newly prioritized assets still lack company-delivered late-stage proof under Relmada ownership.

WatchKey bullets

NDV-01 U.S.

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $8 (p=45%)

Bull/Bear spread: +46% / -34%

Vs latest close: Bull +46% · Base +9% · Bear -34%

Scenario probabilities

Bull Target: $10 (p=25%)Base Target: $8 (p=45%)Bear Target: $5 (p=30%)

Commentary

Current sentiment is cautiously constructive but not strong. The March 2026 10-K and related 8-K corporate update show a company that has pivoted away from REL-1017, is centered on NDV-01 and sepranolone, and has near-term liquidity for planned 2026 milestones, yet forward visibility is still mainly management-timeline based rather than data-driven [#10-K-2026-03-19] [#8-K-2026-03-20].

As of 2026-04-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway supports near-term milestones but likely not a full multi-program buildout without more capital

Scenarios

Bull Target (Scenario probability)

$10 / p=25% prob

Base Target (Scenario probability)

$8 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Price $7 as of 2026-06-01

Nearest Scenario: Base (∆ 9%)

Targets vs latest close: Bull +46% · Base +9% · Bear -34%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
NDV-01 U.S. IND clearance / Phase 3 start target in mid-2026
Relmada said in its 2025 Form 10-K that it expects NDV-01 U.S. IND clearance and Phase 3 initiation for high-risk BCG-unresponsive NMIBC in mid-2026; hitting that timeline would be the first material execution proof for the post-REL-1017 strategy shift [#10-K-2026-03-19].
Prob 45.00% • Move 28.00% • Priced-in 35.00%
EVENT2026-06-30
Sepranolone Phase 2b study initiation target in PWS
The 2025 Form 10-K says sepranolone is Phase 2b-ready and that Relmada expects to initiate a Phase 2b study in Prader-Willi syndrome in mid-2026; launch of that study would broaden the pipeline but remains an execution milestone rather than clinical proof [#10-K-2026-03-19].
Prob 50.00% • Move 18.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway supports near-term milestones but likely not a full multi-program buildout without more capital
2027-03-19
Relmada reported about $93.0 million of cash, cash equivalents, and short-term investments at December 31, 2025, and stated existing resources should fund operations for at least 12 months from issuance of the audited financials, while noting later trial scope will affect the timing of additional financing or partnering; that lowers immediate distress risk but leaves medium-term dilution or deal dependence in view [#10-K-2026-03-19].
Prob 70% • Move -20% • Priced-in 55%

Risks

Additional financing or partnering may be needed beyond the stated 12-month funding horizon.
Mid-2026 IND and trial-start timelines may slip.
Newly prioritized assets still lack company-delivered late-stage proof under Relmada ownership.
Small-cap biotech sentiment can re-rate quickly on regulatory, enrollment, or dilution updates.

Peers

Symbol	Summary
TLSI	TriSalus is only a loose comp, but it is another small-cap life-sciences name where valuation is driven more by clinical execution and financing cadence than current earnings.
ALLO	Allogene is not indication-matched, yet it is a useful event-volatility comparator because investors similarly focus on trial progress, regulatory timing, and balance-sheet durability.
PALI	Palisade is also a loose small-cap biotech comparator; like RLMD, sentiment can swing sharply on milestone timing and capital needs rather than established commercial traction.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-17